15 Chinese Companies to Watch in April 2022 – Healthcare

Healthcare Author: Siren Chen Editor: Tao Ni May 12, 2022 11:03 AM (GMT+8)

Editor's note: We at EqualOcean tracked the major funding rounds or industry events that took place in China’s healthcare space in April 2022. And the following is a list of deals that we have selected for you, based on a number of criteria including the funding amount, the financial backers, and the segments in which the startups operate.

Wonderful health


Ammunition Life Technology (Chinese: 艾米森), a high-tech healthcare enterprise, raised more than CNY 100 million (USD 15.12 million) in a Series C financing round from CCB International, Wuhan Hi-Tech, Sanya Xuanpan and other investors in late April. It was founded in 2015, focusing on non-invasive screening and early detection for high-incidence malignant tumors.

TG Immune Pharma

TG Immune Pharma (Chinese: 天港免疫) completed its Pre-Series A funding round worth over CNY 100 million (USD 15.12 million) in late April. Casstar and Innoval Capital were the co-investors, with Hefei Industry Investment Group, Efung Capital, Tiantu Capital, Guoyuan Innovation Investment and other investors following suit. As a quasi-unicorn company in immunotherapy for cancer, TG Immune Pharma is committed to developing its original innovation ability.

Lingfu Bio

Lingfu Bio (Chinese: 灵赋生物) received more than CNY 200 million (USD 30.24 million) on April 25 from investors including China Life Equity Investment and Legend Capital. Other investors like Chang Development, Puhua Capital, and Safe Pharmaceutical were also involved. The company has bagged nearly CNY 50 million in its angel financing round previously. Co-incubated by several well-known companies and laboratory animal industry expert teams in 2021, Lingfu Biotechnology focuses on becoming the first scientific research service provider in China.


Bostal (Chinese: 玻思韬) completed in mid-April an over CNY 100 million (USD 15.12 million) Series B1 round of financing led by Huatai Trust Fund under Huatai Zijin Investment, with participation from Chuangyu Ming’an Fund, Zhongfu Yide Fund and Jet Biofil. Founded in 2013, Bostal is a high-tech pharmaceutical enterprise focusing on the R&D of international pharmaceutical preparations and new controlled release drug delivery system technology.


Biosurf (Chinese: 百赛飞), a functional biological coating developer, raised over CNY 100 million (USD 15.12 million) in a Series B financing round from Huatai Zijin Investment, Guoqian Venture, HYView Group, Science and Innovation Fund of Suzhou Industrial Park and other investors on April 15. The previous shareholder, Essence Capital, increased its equity. Biosurf was founded in 2017 and has established the first professional technical service platform covering the whole industrial chain of functional biological coating in China.

Baylx Biotechnology

Baylx Biotechnology (Chinese: 贝来生物) completed Series B and Series B+ financing rounds for a combined CNY 300 million (USD 45.36 million) on April 15. The Series B round was jointly led by SDIC Venture Capital and Detong Capital, followed by New Hope Industry Investment. The Series B + round was led by Huajin Capital, with the existing shareholders SDIC Venture Capital and New Hope Industry Investment following suit. Founded in 2015, Baylx is a national high-tech enterprise dedicated to the research of stem cells and regenerative medicine, R&D of stem cell new drugs and clinical transformation.

Synthgene Biotechnology

Synthgene Biotechnology (Chinese: 申基生物) completed a Series A+ financing round in early April. This round of financing was jointly led by Lake Bleu Capital and LYFE Capital. The existing shareholders Sherpa Healthcare Partners and Legend Star continued to make additional investments. Previously, the Series A1 financing round was jointly invested by Swiss China Corp, Sherpa Healthcare Partners and Legend Star. The two rounds of financing accumulated over CNY 300 million (USD 45.36 million). Founded in 2018, Synthgene biotech focuses on providing raw materials used in the upstream section of life sciences.


Raymonpharma (Chinese:锐明新药), an ophthalmic drugs developer, closed its Series B round of funding worth over CNY 100 million (USD 15.12 million) on April 6. This round was led by CR-CP Life Science Fund and backed by Jinding Capital. Raymonpharma is committed to small molecule ophthalmic innovative drugs.

Arthur Group

Arthur Group (Chinese:亚瑟医药) announced the completion of a Series A financing round of over CNY 100 million (USD 15.12 million) led by Addor Capital, with participation from Changxing Financial Holding, Jiaxing Science and Technology City Fund, Ruiying Holdings and other private equity funds. Founded in 2020, Arthur Group is a high-tech innovative pharmaceutical technology enterprise focusing on the development, production and sales of high-end drugs.


METiS (Chinese: 剂泰医药), an AI drug and delivery system developer, raised USD 150 million in two rounds of financing on April 6 from PICC Capital and China Life Private Equity Investment, with participation from Sequoia China, 5Y Capital, CMB International, Lightspeed China Partners, Monolith, Frees Fund and other investors. Founded in 2020 and incubated by XtalPi (Chinese: 晶泰科技), a tech-driven drugmaker, METiS has completed five rounds of financing.

15 start ups.png.png

Reliable Med

Reliable Med (Chinese: 瑞莱普) grabbed its CNY 100 million (USD 15.12 million) Series A2 financing round from CITIC PE Fund and Morning Spring Venture on April 1. The existing backers Legend Capital and Chende Capital made follow-on investments. Founded in 2019, Reliable Med is committed to promoting the implementation of innovative detection applications based on mass spectrometry technology.

CATUG Biotechnology

CATUG Biotechnology (Chinese: 楷拓生物) raised tens of millions of USD from  a Series A financing round on April 25 from Genesis Capital, InnoVision Capital, Oriza Holdings, Lanhu Capital, Tsing Song Capital and Northern Light Venture Capital. The funds will be used to construct a plasmid and mRNA industrialization base and a new technology R&D platform, and continuously improve the capacity and scale of the one-stop CDMO (Contract Design & Manufacture Organization) service platform.

Elixir Clinical Research

Contract research organization Elixir Clinical Research (Chinese: 圣方医药研发) closed its Series A round of funding worth USD 52 million on April 22. This round of financing was jointly invested by LYFE Capital, Sinovation Ventures and Chow Tai Fook.


AI protein design platform MoleculeMind (Chinese: 分子之心) completed an angel round of financing for tens of millions of USD on April 18. This round of financing is led by Sequoia China, with participation from Baidu Ventures, Life Science Park Innovation Fund, Neux Capital and Future Innovation Fund. The company was established by Professor Xu Jinbo who worked for Toyota Technological Institute at Chicago. He was also an assistant professor at the Computation Institute at the University of Chicago as well as a visiting professor at the Biomedical Pioneering Innovation Center of Peking University.

LTZ Therapeutics

LTZ Therapeutics (Chinese: 泽安生物医药) completed on April 7 a USD 17 million Pre-Series A round of financing led by Xianfeng Cowin Investment, with Qiming Venture Partners and Tigermed following suit. LTZ is a biotechnology company focusing on immunotherapy and was co-founded by three new drug development pioneers, Dr. Robert Li, Dr. Martin Treder and Dr. Zhou Jianhui.